BlueCrest Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

BlueCrest Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,903	Closed	-$115K	–	828
2018 Q3	$115K	Buy	+1,903	New	+$107K	﹤0.01%	1370
2018 Q2	–	Sell	-15,916	Closed	-$923K	–	1455
2018 Q1	$923K	Buy	15,916 +12,747	+402%	+$794K	0.03%	512
2017 Q4	$111K	Buy	+3,169	New	+$104K	﹤0.01%	756

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlueCrest Capital Management's ADVM Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2018, closing a stake of 1,903 shares — an estimated $115K sold.

BlueCrest Capital Management first reported a position in ADVM in Q4 2017 and held it in 3 quarters. The position peaked at $923K in Q1 2018. 86 funds tracked by Wall St. Rank hold ADVM as of Q4 2018.

BlueCrest Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2018 after selling out during the quarter.
BlueCrest Capital Management sold 1,903 Adverum Biotechnologies shares in Q4 2018, an estimated $115K.
BlueCrest Capital Management first reported a position in Adverum Biotechnologies in Q4 2017 and held it in 3 quarters.
BlueCrest Capital Management's Adverum Biotechnologies position peaked at $923K in Q1 2018.
86 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.